<DOC>
	<DOC>NCT02737930</DOC>
	<brief_summary>The purpose of this study is to determine whether fluoxetine, a selective serotonin reuptake inhibitor commonly used for depression, enhances visual recovery after an acute ischemic stroke.</brief_summary>
	<brief_title>Fluoxetine for Visual Recovery After Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>MRIconfirmed acute ischemic stroke resulting in an isolated homonymous visual field loss. Known hypersensitivity to fluoxetine or other selective serotonin reuptake inhibitors National Institutes of Health Stroke Scale score greater than 5 Premorbid modified Rankin Scale score greater than 2 Premorbid monocular or binocular visual field deficits Premorbid retinopathy or optic neuropathy Premorbid depression History of cognitive impairment, dementia, or neurodegenerative disorder History of seizure disorder History of mania or hypomania History of hyponatremia History of angleclosure glaucoma or elevated intraocular pressure Current alcohol abuse or impaired liver function Current use of an antidepressant medication Current use of a medication likely to have an adverse interaction with fluoxetine Current use of a medication likely to impair poststroke recovery Contraindication to MRI Pregnancy or lactation Hemorrhagic transformation of the index stroke, resulting in mass effect Enrollment in another clinical trial at the time of the index stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>Homonymous hemianopia</keyword>
	<keyword>Homonymous quadrantanopia</keyword>
	<keyword>Visual field loss</keyword>
	<keyword>Post-stroke recovery</keyword>
	<keyword>Fluoxetine</keyword>
	<keyword>Selective serotonin reuptake inhibitor</keyword>
</DOC>